Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2003

View Archived Issues

GPI-15427 improves function of poorly preserved livers in animal model

Efficacy and safety of SU-11248 assessed in advanced solid tumors

Atlizumab in secondary osteoporosis and rheumatoid arthritis

Reepithelialization of second degree burns enhanced in pigs administered CNI-1493

BPC-157 promotes healing of bone and muscle in preclinical models

Antitumor effects described for CA4P combined with carboplatin in advanced cancer

Nonhypercalcemic vitamin D analogues newly synthesized at Schering AG

Three series of PDE4 inhibitors and their use claimed by Tanabe Seiyaku researchers

New cathepsin S inhibitors described by Aventis and AxyS (Celera Genomics)

Adenosine A2B receptor antagonists with utility in asthma, diarrhea, etc.

Merck Frosst and AxyS team claims novel cathepsin K inhibitors in recent patent

Novel anti-HIV agents prepared and tested by JT scientists

Nippon Shinyaku patent covers new TGF-beta antagonists

Heart drug may combat fungal infections

Preliminary evidence of immune response reported in Norelin trial

Positive phase II data for Neurodex in neuropathic pain

Vion terminates phase I TAPET trial

Fibrostat phase IIb trial cleared to commence

PYM-50028 completes phase I testing, advances to phase II

Concept validation study confirms potential of M-40403 as safe and active compound

Positive topline phase III results for oritavancin in bacterial skin infections

DPP IV inhibition as a strategy for controlling type 2 diabetes

PTP1B inhibitor IDD-2846 may be useful for improving insulin resistance in diabetes

Japanese group characterizes TY-51501 as potential new drug for type 2 diabetes

FR-221647, a novel ADA inhibitor with improved pharmacokinetics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...